What is Cardiotrack?
Cardiotrack operates at the intersection of telemedicine and advanced diagnostic hardware. By leveraging its proprietary Ethos platform, the company creates a cohesive ecosystem that bridges the gap between remote patient monitoring and clinical decision-making. Its core offerings, including portable ECG units and the Cardiac Risk Assessment (CRA) test, provide critical data points for healthcare providers, insurers, and corporate wellness programs. By streamlining the diagnostic process, Cardiotrack addresses the growing demand for efficient, data-driven cardiac care in an increasingly digital medical landscape.
How much funding has Cardiotrack raised?
Cardiotrack has raised a total of $2M across 1 funding round:
Series A
$2M
Series A (2024): $2M, investors not publicly disclosed
Key Investors in Cardiotrack
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Cardiotrack?
With this major strategic investment, Cardiotrack is poised to accelerate its market penetration and enhance its technological stack. The company is expected to focus on expanding the interoperability of the Ethos platform, potentially integrating a broader array of third-party IoT devices to solidify its position as a leader in the diagnostic ecosystem. As the firm transitions into a more mature operational phase, the focus will likely shift toward scaling its B2B partnerships with re-insurers and large-scale healthcare networks, ensuring that its diagnostic tools become a standard component of preventative cardiac health management.
See full Cardiotrack company page
